Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 27 April 2007. doi:10.1136/jcp.2006.040113
Journal of Clinical Pathology 2007;60:1187-1194
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

REVIEWS

Clinical relevance of molecular genetics to paediatric sarcomas

Olga Slater1 and Janet Shipley2

1 Paediatric Oncology, The Institute of Cancer Research, Sutton, Surrey, UK
2 Molecular Cytogenetics, The Institute of Cancer Research, Sutton, Surrey, UK

Correspondence to:
Dr Janet Shipley, Molecular Cytogenetics, The Institute of Cancer Research, 15 Cotswold Rd, Sutton, Surrey SM2 5NG, UK; janet.shipley{at}icr.ac.uk

ABSTRACT

The application of cytogenetic and molecular genetic analyses to paediatric sarcomas has identified a number of characteristic changes associated with types and subtypes of sarcomas. This has led to increased understanding of the underlying molecular biology of some sarcomas and provided an important adjunct to standard morphological and immunohistochemical diagnoses. Characteristic genetic abnormalities, particularly specific chromosome translocations and associated fusion genes, have diagnostic and in some cases prognostic value. There is also the potential to detect micrometastastic disease. Fusion genes are most readily detected by fluorescence in situ hybridisation and reverse transcription-PCR technologies. The expression profiles of tumours with specific fusion genes are characteristically similar and the molecular signatures of sarcomas are also proving to be of diagnostic and prognostic value. Furthermore, fusion genes and other emerging molecular events associated with sarcomas represent potential targets for novel therapeutic approaches which are desperately required to improve the outcome of children with certain categories of sarcoma, including rhabdomyosarcomas and the Ewing’s family of tumours. Increased understanding of the molecular biology of sarcomas is leading towards more effective treatments which may complement or be less toxic than conventional radiotherapy and cytotoxic chemotherapy. Here we review paediatric sarcomas that have associated molecular genetic changes which can increase diagnostic and prognostic accuracy and impact on clinical management.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Kratz, C P, Holter, S, Etzler, J, Lauten, M, Pollett, A, Niemeyer, C M, Gallinger, S, Wimmer, K (2009). Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome. J. Med. Genet. 46: 418-420 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Pathology jobs

Pathology jobs